Serveur d'exploration Stress et Covid

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy

Identifieur interne : 001723 ( Main/Exploration ); précédent : 001722; suivant : 001724

NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy

Auteurs : M. Munoz [Espagne] ; R. Covenas [Espagne]

Source :

RBID : Pascal:12-0004338

Descripteurs français

English descriptors

Abstract

The neuropeptide substance P (SP) shows a widespread distribution in both the central and peripheral nervous systems and it is known that after binding to the neurokinin-1 (NK-1) receptors, SP regulates many biological functions in the central nervous system such as emotional behaviour, stress, depression, anxiety, emesis, migraine, alcohol addiction and neurodegeneration. SP has been also implicated in pain, inflammation, hepatotoxicity and in virus proliferation, and it plays an important role in cancer (e.g., tumour cell proliferation, angiogenesis, and the migration of tumour cells for invasion and metastasis). By contrast, it is known that after binding to NK-1 receptors, NK-1 receptor antagonists specifically inhibit the above-mentioned biological functions mediated by SP. Thus, these antagonists exert an anxyolitic, antidepressant, antiemetic, antimigraine, antialcohol addiction or neuroprotector effect in the central nervous system, and they play a role in analgesic, antiinflammatory, hepatoprotector processes and in antivirus proliferation. Regarding cancer, NK-1 receptor antagonists exert an antitumour action (inducing tumour cell death by apoptosis), and induce antiangiogenesis and inhibit the migration of tumour cells. It is also known that NK-1 receptors have a widespread distribution and that they are overexpressed in tumour cells. Thus, NK-1 receptor antagonists are molecularly targeted agents. In general, current drugs have a single therapeutic effect, although less commonly they may exert several. However, the data reported above indicate that NK-1 receptor antagonists are promising drugs, exerting many therapeutic effects (the action of such antagonists is dose-dependent and, depending on the concentration, has more positive effects). In this review, we update the multiple therapeutic effects exerted by NK-1 receptor antagonists.


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy</title>
<author>
<name sortKey="Munoz, M" sort="Munoz, M" uniqKey="Munoz M" first="M." last="Munoz">M. Munoz</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Research Laboratory on Neuropeptides, Virgen del Rocio University Hospital</s1>
<s2>Sevilla</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
<wicri:noRegion>Sevilla</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Covenas, R" sort="Covenas, R" uniqKey="Covenas R" first="R." last="Covenas">R. Covenas</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Institute of Neurosciences of Castilla y León (INCYL), Laboratory of Neuroanatomy of the Peptidergic Systems (Lab. 14)</s1>
<s2>Salamanca</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
<wicri:noRegion>Salamanca</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">12-0004338</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 12-0004338 INIST</idno>
<idno type="RBID">Pascal:12-0004338</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000079</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000171</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000055</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000055</idno>
<idno type="wicri:doubleKey">0929-8673:2011:Munoz M:nk:receptor:antagonists</idno>
<idno type="wicri:Area/Main/Merge">001725</idno>
<idno type="wicri:Area/Main/Curation">001723</idno>
<idno type="wicri:Area/Main/Exploration">001723</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy</title>
<author>
<name sortKey="Munoz, M" sort="Munoz, M" uniqKey="Munoz M" first="M." last="Munoz">M. Munoz</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Research Laboratory on Neuropeptides, Virgen del Rocio University Hospital</s1>
<s2>Sevilla</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
<wicri:noRegion>Sevilla</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Covenas, R" sort="Covenas, R" uniqKey="Covenas R" first="R." last="Covenas">R. Covenas</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Institute of Neurosciences of Castilla y León (INCYL), Laboratory of Neuroanatomy of the Peptidergic Systems (Lab. 14)</s1>
<s2>Salamanca</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
<wicri:noRegion>Salamanca</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Current medicinal chemistry</title>
<title level="j" type="abbreviated">Curr. med. chem.</title>
<idno type="ISSN">0929-8673</idno>
<imprint>
<date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Current medicinal chemistry</title>
<title level="j" type="abbreviated">Curr. med. chem.</title>
<idno type="ISSN">0929-8673</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Addiction</term>
<term>Analgesic</term>
<term>Antagonist</term>
<term>Antialcohol drug</term>
<term>Antidepressant agent</term>
<term>Antiemetic</term>
<term>Antiinflammatory agent</term>
<term>Antineoplastic agent</term>
<term>Antiviral</term>
<term>Aprepitant</term>
<term>Biological activity</term>
<term>Dapitant</term>
<term>Drug addiction</term>
<term>Fosaprepitant</term>
<term>Lanepitant</term>
<term>Migraine</term>
<term>NK1 Tachykinin receptor</term>
<term>Neuropeptide</term>
<term>Nolpitantium besilate</term>
<term>Non peptide compound</term>
<term>Pain</term>
<term>Peptide hormone</term>
<term>Peptides</term>
<term>Piperidine derivatives</term>
<term>Psychotropic</term>
<term>Review</term>
<term>Substance P</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Récepteur tachykinine NK1</term>
<term>Antagoniste</term>
<term>Substance P</term>
<term>Antidépresseur</term>
<term>Analgésique</term>
<term>Antiviral</term>
<term>Antialcoolique</term>
<term>Toxicomanie</term>
<term>Addiction</term>
<term>Antiinflammatoire</term>
<term>Anticancéreux</term>
<term>Article synthèse</term>
<term>Activité biologique</term>
<term>Composé non peptide</term>
<term>Antiémétique</term>
<term>Migraine</term>
<term>Aprépitant</term>
<term>Dapitant</term>
<term>Fosaprépitant</term>
<term>Lanépitant</term>
<term>Bésilate de nolpitantium</term>
<term>Dérivé de la pipéridine</term>
<term>Hormone peptide</term>
<term>Neuropeptide</term>
<term>Psychotrope</term>
<term>Peptide</term>
<term>Douleur</term>
<term>L 732138</term>
<term>Tryptophane dérivé</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Toxicomanie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The neuropeptide substance P (SP) shows a widespread distribution in both the central and peripheral nervous systems and it is known that after binding to the neurokinin-1 (NK-1) receptors, SP regulates many biological functions in the central nervous system such as emotional behaviour, stress, depression, anxiety, emesis, migraine, alcohol addiction and neurodegeneration. SP has been also implicated in pain, inflammation, hepatotoxicity and in virus proliferation, and it plays an important role in cancer (e.g., tumour cell proliferation, angiogenesis, and the migration of tumour cells for invasion and metastasis). By contrast, it is known that after binding to NK-1 receptors, NK-1 receptor antagonists specifically inhibit the above-mentioned biological functions mediated by SP. Thus, these antagonists exert an anxyolitic, antidepressant, antiemetic, antimigraine, antialcohol addiction or neuroprotector effect in the central nervous system, and they play a role in analgesic, antiinflammatory, hepatoprotector processes and in antivirus proliferation. Regarding cancer, NK-1 receptor antagonists exert an antitumour action (inducing tumour cell death by apoptosis), and induce antiangiogenesis and inhibit the migration of tumour cells. It is also known that NK-1 receptors have a widespread distribution and that they are overexpressed in tumour cells. Thus, NK-1 receptor antagonists are molecularly targeted agents. In general, current drugs have a single therapeutic effect, although less commonly they may exert several. However, the data reported above indicate that NK-1 receptor antagonists are promising drugs, exerting many therapeutic effects (the action of such antagonists is dose-dependent and, depending on the concentration, has more positive effects). In this review, we update the multiple therapeutic effects exerted by NK-1 receptor antagonists.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Espagne</li>
</country>
</list>
<tree>
<country name="Espagne">
<noRegion>
<name sortKey="Munoz, M" sort="Munoz, M" uniqKey="Munoz M" first="M." last="Munoz">M. Munoz</name>
</noRegion>
<name sortKey="Covenas, R" sort="Covenas, R" uniqKey="Covenas R" first="R." last="Covenas">R. Covenas</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001723 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001723 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    StressCovidV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:12-0004338
   |texte=   NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed May 6 16:44:09 2020. Site generation: Sun Mar 28 08:26:57 2021